Info@ThinkPinkRocks.com

AstraZeneca’s ticagrelor receives Class I recommendation from ESC

AstraZeneca today announced that ticagrelor, an oral antiplatelet medicine, received a Class I recommendation from the European Society of Cardiology (ESC) in the revised “Guidelines on the Management of Acute Myocardial Infarction in Patients Presenting with Persistent ST-Segment Elevation (STEMI)” guidelines.

Read the article:
AstraZeneca’s ticagrelor receives Class I recommendation from ESC

Share

Leave a Reply

Solve : *
23 + 18 =